Head to head

CJC-1295 with DAC vs Hexarelin

GH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Not an either/or

CJC-1295 with DAC and Hexarelin appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you do have to pick one, let route and schedule decide it — CJC-1295 with DAC is subcutaneous, once a week; Hexarelin is subcutaneous, intramuscular, once daily — because the evidence does not separate them cleanly enough to do it for you.

What you are actually choosing between

Before anything else: the dataset lists CJC-1295 with DAC and Hexarelin in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is muscle growth, injury repair, and recovery and sleep. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 with DAC rates 4/5 for muscle growth and Hexarelin rates 4/5.

The evidence

Hexarelin sits one step firmer: controlled human trials behind it, without an approval — human GH-response data is real, but the response blunts within weeks. CJC-1295 with DAC has some human data, but it is small, old, or uncontrolled — phase 1 single-dose studies only; development was discontinued. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

How they differ in practice

CJC-1295 with DAC is a subcutaneous injection; Hexarelin is a subcutaneous injection and an intramuscular injection. Both are injected, so route does not decide this one.

Kinetics are not close. CJC-1295 with DAC has a half-life of 7 days against Hexarelin's 1 h — more than two orders of magnitude — which is why one is dosed once a week and the other once daily. A long half-life means a steadier level and a mistake you cannot take back for days; a short one means timing matters and a bad day washes out fast.

Committed time differs: CJC-1295 with DAC runs 12 weeks, Hexarelin runs 4 weeks.

Risk and difficulty

CJC-1295 with DAC is rated intermediate here and Hexarelin advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 with DAC

Dosed once weekly at 1 to 2 mg, which is how it is overwhelmingly run in practice: the albumin binding makes the weekly total the meaningful quantity, and splitting it across the week buys nothing. A GHRH (1-29) analogue carrying a Drug Affinity Complex maleimide that binds serum albumin, which is the ONLY reason it differs from the no-DAC version: the terminal half-life runs roughly 6 to 8 days instead of minutes, so a single dose produces a sustained rise in GH and IGF-1 rather than a discrete pulse. Phase 1 human dosing studies used single subcutaneous doses of about 30 to 250 mcg/kg. Development was discontinued and it is NOT approved by any regulator; consumer supply is research-chemical grade. Because exposure is continuous rather than pulsatile, it is the less physiologic of the two CJC-1295 forms and carries more of the water-retention and glucose signal.

Hexarelin

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist and one of the most potent GH secretagogues studied in humans, with additional cardiac data. Its defining practical problem is tachyphylaxis: repeated dosing blunts the GH response over roughly two to four weeks, which is why it is cycled short rather than run continuously. It also lacks the selectivity of ipamorelin, so prolactin and cortisol elevation are expected at higher doses.

Side by side

The numbers

CJC-1295 with DAC compared with Hexarelin
Attribute	CJC-1295 with DAC	Hexarelin
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous, Intramuscular
Dose range	1 mg–2 mg (typical 1.5 mg)	50 mcg–200 mcg (typical 100 mcg)
Frequency	Once a week	Once daily
Half-life	7 days	1 h
Cycle length	12 weeks	4 weeks
Experience	Intermediate	Advanced
Evidence	Limited human data	Controlled human trials
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Water retention and puffiness, more pronounced than with short-acting GHRHs Injection site redness or swelling Head rush, flushing or transient dizziness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Reduced insulin sensitivity and higher fasting glucose with sustained elevation Lethargy or headache, often reported in the first week	Marked receptor desensitisation — the GH response falls off within a few weeks of continuous daily use, so cycles are kept short with washout periods Raises prolactin and cortisol more than ipamorelin does Strong hunger spike within 20 to 30 minutes of dosing Water retention, puffiness and numb or tingling hands Head rush, flushing or transient light-headedness after injection Injection site irritation

Turn a typical dose into a mark on the syringe: CJC-1295 with DACHexarelin

Goals

Where they overlap, and where they do not

Goal	CJC-1295 with DAC	Hexarelin
muscle growth	CJC-1295 with DAC: 4/5	Hexarelin: 4/5
injury repair	CJC-1295 with DAC: 3/5	Hexarelin: 3/5
recovery and sleep	CJC-1295 with DAC: 3/5	Hexarelin: 3/5
fat loss	CJC-1295 with DAC: 2/5	Hexarelin: 2/5
longevity	CJC-1295 with DAC: 2/5	Hexarelin: 1/5

They overlap on 5 goals and diverge on 0. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 with DACMechanism, protocol, storage, sources.MonographHexarelinMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.